SEARCH:   Advanced

Blood, 1 November 2008, Vol. 112, No. 9, pp. 3574-3581. Prepublished online as a Blood First Edition Paper on July 7, 2008; DOI 10.1182/blood-2008-02-140095. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-02-140095v1 112/9/3574    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ciceri, F. Articles by Rocha, V. Search for Related Content PubMed PubMed Citation Articles by Ciceri, F. Articles by Rocha, V. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 25, 2008 Accepted June 21, 2008 A survey of fully-haploidentical hematopoietic stem cells transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients transplanted in remission Fabio Ciceri*, Myriam Labopin, Franco Aversa, Jakob M Rowe, Donald Bunjes, Philippe Lewalle, Arnon Nagler, Paolo Di Bartolomeo, Joao F. Lacerda, Maria Teresa Lupo Stanghellini, Emmanuelle Polge, Francesco Frassoni, Massimo F Martelli, and Vanderson Rocha Hematology and BMT Unit, San Raffaele Scientific Institute, Milano, Italy Universite Pierre et Marie Curie Paris 6, Hopital Saint Antoine AP-HP, Paris, France Hematology, University of Perugia, Perugia, Italy Israel Institute of Technology, Rambam Medical Centre Technion, Haifa, Israel Hematology, University of Ulm, Ulm, Germany Institut Bordet, Universite libre de Bruxelles, Bruxelles, Belgium Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel BMT Unit, Ospedale Civile, Pescara, Italy Hematology, Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal Hematology, H San Martino, Genova, Italy Hopital Saint-Louis, Paris, France * Corresponding author; email: ciceri.fabio{at}hsr.it. Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) is an alternative treatment to patients with high-risk acute leukemia lacking a HLA-matched donor. We analyzed 173 adults with myeloid (AML) and 93 with lymphoblastic leukemia (ALL) receiving an Haplo-HSCT in Europe. All grafts were T-cell depleted peripheral blood progenitor cells from a direct family or other related donor. At transplantation there were 25 patients with AML in CR1, 61 in CR2 and 87 in non-remission, and 24 with ALL in CR1, 37 in CR2 and 32 in non-remission. Median follow-up was 47 months in AML and 29 months in the ALL groups. Engraftment was observed in 91% of the patients. Leukemia-free survival (LFS) at 2-years was 48±10%, 21±5% and 0% for patients with AML transplanted in CR1, CR2 and non-remission, and 13±7%, 30±8%, and 7±5% in ALL patients, respectively. In a risk-factor analysis for patients transplanted in remission, in the AML group, LFS was increased when the donors were siblings or parents and in the ALL group, if both recipient and donor were CMV seronegative. In conclusion, Haplo-HSCT can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a HLA matched donor. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Vago, S. K. Perna, M. Zanussi, B. Mazzi, C. Barlassina, M. T. L. Stanghellini, N. F. Perrelli, C. Cosentino, F. Torri, A. Angius, et al. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation N. Engl. J. Med., July 30, 2009; 361(5): 478 - 488. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020